Sukriti Vishwas

About

Dr. Sukriti Vishwas, Ph.D., is an Assistant Professor at Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India, with a robust background in pharmacology and pharmaceutical sciences. He holds a Bachelor of Pharmacy from VNS College of Pharmacy, Bhopal, India; a Master of Pharmacy in Pharmacology from J.S.S. College of Pharmacy, Ooty, Tamil Nadu, India; and a Ph.D. in Pharmaceutical Sciences from Lovely Professional University, Jalandhar, Punjab, India. Recognized as one of the World's Top 2% Scientists by Stanford University (2025), Dr. Vishwas has authored 120 peer-reviewed research papers with a cumulative impact factor of plus 550, contributed to five book chapters, secured 5 published patents, 1 granted patent, and 50 granted copyrights. His accolades include the Research Appreciation Award from Lovely Professional University on September 5, 2023, and September 5, 2024, as well as the Young Research Scientist Award from Chameli Devi Institute of Pharmacy, Indore, India, on March 23, 2024. Actively engaged in global academia, he has participated in prestigious conferences such as the MSPP 34th Scientific Meeting 2021 at Monash University Malaysia and the Alzheimer’s Association International Conference (AAIC 2023), demonstrating expertise in research methodology, drug development, scientific writing, and mentoring future pharmaceutical professionals.

Employment

• Chitkara University
  2025 - Present
• Lovely Professional University
  2020 - 2025

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (59)

• Small nucleolar RNAs: Emerging therapeutic and diagnostic frontiers in Alzheimer’s disease
  Drug Discovery Today 2026 0 citations DOI: 10.1016/j.drudis.2026.104771
  +Save
• Protein and peptide based nanotherapeutics for the management of Alzheimer’s disease: Current insights and future directions
  Ageing Research Reviews 2026 2 citations DOI: 10.1016/j.arr.2025.103000
  +Save
• Interplay between RNA m6A modification and transglutaminase 2 inhibitor effects on mitophagy dysfunction in Alzheimer’s disease
  Drug Discovery Today 2026 0 citations DOI: 10.1016/j.drudis.2026.104748
  +Save
• Modern Perspectives of Ultrasound-Based Drug Delivery
  Transdermal Applications of Minimally Invasive Drug Delivery Systems 2025 2 citations DOI: 10.1007/978-981-96-6275-3_4
  +Save
• Unraveling the Role of Repurposed Drugs in the Treatment of Acne: Success so Far and the Road Ahead
  Drug Development Research 2025 6 citations DOI: 10.1002/ddr.70057
  +Save
• Dissolving microneedles as emerging tools in delivery of biological macromolecules: Current practices and future opportunities
  Journal of Drug Delivery Science and Technology 2025 5 citations DOI: 10.1016/j.jddst.2025.107259
  +Save
• Quality by design tailored development of xanthohumol-loaded nanoemulsion: characterization and evaluation of in vitro antioxidant potential
  Chemical Papers 2025 0 citations DOI: 10.1007/s11696-025-04260-9
  +Save
• Tailoring the biomarkers of Alzheimer’s disease using a gut microbiome-centric approach: Preclinical, clinical, and regulatory perspectives
  Ageing Research Reviews 2025 10 citations DOI: 10.1016/j.arr.2025.102888
  +Save
• Quantum dots in neurotheranostics for the treatment of Alzheimer’s disease
  Ageing Research Reviews 2025 7 citations DOI: 10.1016/j.arr.2025.102876
  +Save
• Exploring nanoparticular platform in delivery of repurposed drug for Alzheimer’s disease: current approaches and future perspectives
  Expert Opinion on Drug Delivery 2024 10 citations DOI: 10.1080/17425247.2024.2414768
  +Save